Severe toxicity in adult patients with lung cancer under treatment with pemetrexed: a prospective cohort study
| العنوان: | Severe toxicity in adult patients with lung cancer under treatment with pemetrexed: a prospective cohort study |
|---|---|
| المؤلفون: | Maria Alicia Verzura, Esteban Gabriel Jauregui, Paula Scibona, María Guadalupe Pallotta, J.N. Minatta, Heidy Díaz de Arce, Carolina Vázquez, María Orlova, Waldo H. Belloso |
| المصدر: | Journal of Chemotherapy. 31:95-104 |
| بيانات النشر: | Informa UK Limited, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Drug-Related Side Effects and Adverse Reactions, Genotype, medicine.drug_class, 030106 microbiology, Antineoplastic Agents, Pemetrexed, Polymorphism, Single Nucleotide, Severity of Illness Index, Antimetabolite, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Predictive Value of Tests, Internal medicine, medicine, Humans, Pharmacology (medical), Lung cancer, Adverse effect, Prospective cohort study, Methylenetetrahydrofolate Reductase (NADPH2), Aged, Pharmacology, biology, business.industry, Thymidylate Synthase, Middle Aged, medicine.disease, Infectious Diseases, 030220 oncology & carcinogenesis, Methylenetetrahydrofolate reductase, biology.protein, Female, business, Pharmacogenetics, Follow-Up Studies, medicine.drug |
| الوصف: | Pemetrexed is an antimetabolite approved for treatment of non-small cell lung cancer. Harbouring interindividual variability in both the pharmacokinetic and pharmacogenetic profiles may lead to life-threatening toxicities. A prospective cohort study of adult patients initiating treatment with pemetrexed in combination with platinum between 2013 and 2015 were follow up. Primary exposure were the methylenetetrahydrofolate reductase (MTHFR) single base polymorphisms in exon 4 and 7 and 5'-UTR- thymidylate synthase (TYMS) VNTR genotypes, in addition to baseline clinical and demographic variables. We used a Cox regression model to evaluate patient's survival and toxicity experience and its association with both baseline characteristics, and a-priori determined genetic polymorphisms. Seventy two patients were included, 52.7% developed severe hematologic toxicity during follow-up. None of the tested genotypes were significantly associated with the main outcome on multivariate analysis, nor other basal clinical variables. Overall survival between patients experiencing the outcome was not different from those without it, but hospital admissions were more frequent. MTHFR and 5'-UTR-TYMS genotypes were not useful for predicting high grade toxicity events in patients under treatment with pemetrexed. |
| تدمد: | 1973-9478 1120-009X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c3acec786214036f988e552facb59f https://doi.org/10.1080/1120009x.2019.1572287 |
| رقم الأكسشن: | edsair.doi.dedup.....14c3acec786214036f988e552facb59f |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 19739478 1120009X |
|---|